Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Berberine + evodiamine is a combination of two natural alkaloids, berberine (from Coptis chinensis/Rhizoma Coptidis) and evodiamine (from Evodia rutaecarpa/Fructus Evodiae), used primarily in traditional Chinese medicine. This combination has demonstrated synergistic effects in preclinical studies for metabolic disorders such as obesity and non-alcoholic fatty liver disease (NAFLD), as well as anticancer activity against various cancer cell lines. Mechanistically, the combination enhances adipose tissue browning and activates the FGF21/PGC-1α signaling pathway, leading to improved lipid metabolism, reduced hepatic steatosis, better glucose tolerance, and modulation of adipocytokines. In cancer models, it induces cell cycle arrest and apoptosis while attenuating drug resistance mechanisms such as P-glycoprotein overexpression. The pair also exerts epigenetic effects by influencing DNA methyltransferases (DNMTs) and microRNAs involved in tumor progression[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on berberine + evodiamine.